Here at the Lab, we generally do not cover late-stage clinical oncology companies. Still, this time, ArriVent BioPharma ( AVBP ) warrants an exception due to Firmonertinib’s near-term catalysts (Fig. 1) and the Chinese asset’s origin profile. This remains aBuy-side hedge professionals conducting fundamental, income oriented, long term analysis across sectors globally in developed markets. Please shoot us a message or leave a comment to discuss ideas.DISCLOSURE: All of our articles are a matter of opinion, i ...